Yang J, Xiao L, Zhou M, Li Y, Cai Y, Gan Y
Cancer Imaging. 2024; 24(1):86.
PMID: 38965552
PMC: 11229016.
DOI: 10.1186/s40644-024-00735-2.
Thulasi Seetha S, Garanzini E, Tenconi C, Marenghi C, Avuzzi B, Catanzaro M
J Pers Med. 2023; 13(7).
PMID: 37511785
PMC: 10381192.
DOI: 10.3390/jpm13071172.
Thankapannair V, Keates A, Barrett T, Gnanapragasam V
Eur Urol Open Sci. 2023; 49:15-22.
PMID: 36874604
PMC: 9975013.
DOI: 10.1016/j.euros.2022.12.013.
Sushentsev N, Rundo L, Abrego L, Li Z, Nazarenko T, Warren A
Eur Radiol. 2023; 33(6):3792-3800.
PMID: 36749370
PMC: 10182165.
DOI: 10.1007/s00330-023-09438-x.
Lin Y, Liu G, Liu C, Xie H, Wang X, Huang Y
Cancer Med. 2022; 11(15):2875-2885.
PMID: 35289508
PMC: 9359874.
DOI: 10.1002/cam4.4629.
Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.
Lee C, Vellayappan B, Tan C
Br J Radiol. 2021; 95(1131):20210509.
PMID: 34520694
PMC: 8978226.
DOI: 10.1259/bjr.20210509.
Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
Sushentsev N, Rundo L, Blyuss O, Nazarenko T, Suvorov A, Gnanapragasam V
Eur Radiol. 2021; 32(1):680-689.
PMID: 34255161
PMC: 8660717.
DOI: 10.1007/s00330-021-08151-x.
MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance.
Sushentsev N, Rundo L, Blyuss O, Gnanapragasam V, Sala E, Barrett T
Sci Rep. 2021; 11(1):12917.
PMID: 34155265
PMC: 8217549.
DOI: 10.1038/s41598-021-92341-6.
A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.
Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P
J Magn Reson Imaging. 2021; 54(2):462-471.
PMID: 33719168
PMC: 8360022.
DOI: 10.1002/jmri.27599.
The use of hyperpolarised C-MRI in clinical body imaging to probe cancer metabolism.
Woitek R, Gallagher F
Br J Cancer. 2021; 124(7):1187-1198.
PMID: 33504974
PMC: 8007617.
DOI: 10.1038/s41416-020-01224-6.
Effect of lesion diameter and prostate volume on prostate cancer detection rate of magnetic resonance imaging: Transrectal-ultrasonography-guided fusion biopsies using cognitive targeting.
Ozden E, Akpinar C, Ibis A, Kubilay E, Erden A, Yaman O
Turk J Urol. 2020; 47(1):22-29.
PMID: 33016869
PMC: 7815233.
DOI: 10.5152/tud.2020.20238.
Utilization of Multiparametric MRI of Prostate in Patients under Consideration for or Already in Active Surveillance: Correlation with Imaging Guided Target Biopsy.
Yu J, Fulcher A, Winks S, Turner M, Behl W, Ware A
Diagnostics (Basel). 2020; 10(7).
PMID: 32610595
PMC: 7400343.
DOI: 10.3390/diagnostics10070441.
Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions.
McKay R, Feng F, Wang A, Wallis C, Moses K
Am Soc Clin Oncol Educ Book. 2020; 40:1-12.
PMID: 32412803
PMC: 10182417.
DOI: 10.1200/EDBK_279459.
Active Surveillance of Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: A Review of the Current Role and Future Perspectives.
Sklinda K, Mruk B, Walecki J
Med Sci Monit. 2020; 26:e920252.
PMID: 32279066
PMC: 7172004.
DOI: 10.12659/MSM.920252.
PI-RADS: what is new and how to use it.
Dutruel S, Jeph S, Margolis D, Wehrli N
Abdom Radiol (NY). 2020; 45(12):3951-3960.
PMID: 32185445
DOI: 10.1007/s00261-020-02482-x.
Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings.
Beckmann K, OCallaghan M, Vincent A, Cohen P, Borg M, Roder D
Asian J Urol. 2019; 6(4):321-329.
PMID: 31768317
PMC: 6872773.
DOI: 10.1016/j.ajur.2019.03.001.
Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R, Felker E, Kwan L, Barsa D, Zhang H, Sisk A
JAMA Netw Open. 2019; 2(9):e1911019.
PMID: 31509206
PMC: 6739900.
DOI: 10.1001/jamanetworkopen.2019.11019.
Evaluation of prostate MRI: can machine learning provide support where radiologists need it?.
Baur A, Penzkofer T
Eur Radiol. 2019; 29(9):4751-4753.
PMID: 31073858
DOI: 10.1007/s00330-019-06241-5.
Observed racial disparity in the negative predictive value of multi-parametric MRI for the diagnosis for prostate cancer.
Mahran A, Mishra K, Bukavina L, Schumacher F, Quian A, Buzzy C
Int Urol Nephrol. 2019; 51(8):1343-1348.
PMID: 31049779
DOI: 10.1007/s11255-019-02158-6.
Assessment of prostate cancer prognostic Gleason grade group using zonal-specific features extracted from biparametric MRI using a KNN classifier.
Jensen C, Carl J, Boesen L, Langkilde N, Ostergaard L
J Appl Clin Med Phys. 2019; 20(2):146-153.
PMID: 30712281
PMC: 6370983.
DOI: 10.1002/acm2.12542.